Tarextumab

• CAT Number: I042402
• CAS Number: 1359940-55-8
• Purity: ≥95%

Tarextumab (Cat No.: I042402) is a fully human monoclonal antibody that targets Notch2 and Notch3 receptors, key components of the Notch signaling pathway involved in cell differentiation, proliferation, and survival. By inhibiting these receptors, Tarextumab disrupts tumor growth and cancer stem cell maintenance, making it a promising candidate for treating solid tumors such as pancreatic and lung cancers. It has shown potential in combination with chemotherapy to enhance treatment efficacy. Tarextumab is under investigation for targeting tumor-initiating cells and overcoming therapy resistance.

Reference

[1]. Hu ZI, et al. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Med. 2019 Sep;8(11):5148-5157.
[Content Brief]